Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about pharma and health.
Directly affected
- ALNY Alnylam Pharmaceuticals
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ALNY | +28.79% | +30.38% | base | -5.17% | -9.18% | -8.07% | -7.41% |
| XLV | -2.61% | -2.65% | base | +0.46% | +0.32% | -0.02% | +3.05% |
| XBI | -5.24% | -1.88% | base | -1.17% | -3.65% | -1.83% | +0.82% |
| LLY | -7.22% | -6.69% | base | +3.17% | +2.79% | +2.62% | +3.25% |
| JNJ | -4.11% | -2.34% | base | -0.69% | -1.67% | -3.27% | +0.43% |
| PFE | +0.20% | -0.53% | base | +1.84% | +2.54% | +0.10% | +2.80% |
| MRK | -0.71% | -3.06% | base | +2.20% | +1.45% | -1.13% | +2.76% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ALNY | that day | -5.17% | final price |
| ALNY | the next day | -9.18% | final price |
| ALNY | two days later | -8.07% | final price |
| ALNY | three days later | -7.41% | final price |
| ALNY | three days earlier | +30.38% | final price |
| ALNY | five days earlier | +28.79% | final price |
| JNJ | that day | -0.69% | final price |
| JNJ | the next day | -1.67% | final price |
| JNJ | two days later | -3.27% | final price |
| JNJ | three days later | +0.43% | final price |
| JNJ | three days earlier | -2.34% | final price |
| JNJ | five days earlier | -4.11% | final price |
| LLY | that day | +3.17% | final price |
| LLY | the next day | +2.79% | final price |
| LLY | two days later | +2.62% | final price |
| LLY | three days later | +3.25% | final price |
| LLY | three days earlier | -6.69% | final price |
| LLY | five days earlier | -7.22% | final price |
| MRK | that day | +2.20% | final price |
| MRK | the next day | +1.45% | final price |
| MRK | two days later | -1.13% | final price |
| MRK | three days later | +2.76% | final price |
| MRK | three days earlier | -3.06% | final price |
| MRK | five days earlier | -0.71% | final price |
| PFE | that day | +1.84% | final price |
| PFE | the next day | +2.54% | final price |
| PFE | two days later | +0.10% | final price |
| PFE | three days later | +2.80% | final price |
| PFE | three days earlier | -0.53% | final price |
| PFE | five days earlier | +0.20% | final price |
| XBI | that day | -1.17% | final price |
| XBI | the next day | -3.65% | final price |
| XBI | two days later | -1.83% | final price |
| XBI | three days later | +0.82% | final price |
| XBI | three days earlier | -1.88% | final price |
| XBI | five days earlier | -5.24% | final price |
| XLV | that day | +0.46% | final price |
| XLV | the next day | +0.32% | final price |
| XLV | two days later | -0.02% | final price |
| XLV | three days later | +3.05% | final price |
| XLV | three days earlier | -2.65% | final price |
| XLV | five days earlier | -2.61% | final price |
Trades by members of Congress and officials in the stocks in this story
- Donald J Trump, an executive branch official, bought Alnylam Pharmaceuticals (ALNY), worth $1,001 - $15,000 on 28 Aug 2026. That is 63 days before publication. Filed 8 Oct 2026. View the filing.
- Sen. Cory A Booker sold Alnylam Pharmaceuticals (ALNY) (held by a spouse), worth $1,001 - $15,000 on 11 Aug 2026. That is 80 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, bought Alnylam Pharmaceuticals (ALNY), worth $1,001 - $15,000 on 10 Aug 2026. That is 81 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 4 days after publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 10 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 23 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 70 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says” scores 12 out of 100. The score uses 1 sources.